Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.
Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Merck has added two US patents to its CRISPR-Cas9 patent portfolio, and is already seeking licensing and product development partners, the German company announced yesterday, May 11.
Millipore Sigma, the US life sciences business of Merck KGaA, has secured a patent for its CRISPR-chrom technology, bringing its total number of CRISPR-related patents to 23.
IP law firm EIP has enhanced its life science capabilities with the addition of Monika Rai as a partner.
Despite a recent swing in momentum to the University of California, it’s still too early to say who is likely to emerge triumphant in the CRISPR patent battle.
California-based Pacific Biosciences has accused a UK rival of exploiting the coronavirus pandemic in a patent infringement trial.
The US Court of Appeals for the Federal Circuit has ruled that two Illumina DNA detection patents are valid, in a reversal of a California district court.
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
In a victory for the University of California, the European Patent Office has affirmed a CRISPR patent issued to Emmanuelle Charpentier, the University of California, and the University of Vienna.